{"author": "Escobar, HM ", "adress": "Rostock Univ, Dept Med, Clin Hematol Oncol Palliat Care 3, Med Ctr, Rostock, Germany", "emails": ["hugo.murua.escobar@med.uni-rostock.de"], "title": "Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines"}